why choose us

300×250 Ad Slot

Drug FDA Status

Showing 110 of 185 result(s) (Page 11 of 19)
Drug Name: Ebglyss

Active Ingredient: lebrikizumab-lbkz

Approval Date: 2024-09-13

Description: To treat moderate-to-severe atopic dermatitis
Drug Trials Snapshot

Drug Name: Lazcluze

Active Ingredient: lazertinib

Approval Date: 2024-08-19

Description: To treat non-small cell lung cancer
Drug Trials Snapshot

Drug Name: Niktimvo

Active Ingredient: axatilimab-csfr

Approval Date: 2024-08-14

Description: To treat chronic graft-versus-host disease (cGVHD)
Drug Trials Snapshot

Drug Name: Livdelzi

Active Ingredient: seladelpar

Approval Date: 2024-08-14

Description: To treat primary biliary cholangitis (PBC)
Drug Trials Snapshot

Drug Name: Nemluvio

Active Ingredient: nemolizumab-ilto

Approval Date: 2024-08-12

Description: To treat prurigo nodularis
Drug Trials Snapshot

Drug Name: Yorvipath

Active Ingredient: palopegteriparatide

Approval Date: 2024-08-09

Description: To treat hypoparathyroidism
Drug Trials Snapshot

Drug Name: Voranigo

Active Ingredient: vorasidenib

Approval Date: 2024-08-06

Description: To treat Grade 2 astrocytoma or oligodendroglioma
Drug Trials Snapshot

Drug Name: Leqselvi

Active Ingredient: deuruxolitinib

Approval Date: 2024-07-25

Description: To treat severe alopecia areata
Drug Trials Snapshot

Drug Name: Kisunla

Active Ingredient: donanemab-azbt

Approval Date: 2024-07-02

Description: To treat Alzheimer’s disease
Drug Trials Snapshot

Drug Name: Ohtuvayre

Active Ingredient: ensifentrine

Approval Date: 2024-06-26

Description: To treat chronic obstructive pulmonary disease
Drug Trials Snapshot

300×250 Ad Slot